

# Product Information

## Pam<sub>3</sub>Cys-SK<sub>4</sub>KK(Cy5)


For Research Purposes only. Not for use in Humans



<b>Product</b>	L2075
<b>Chemical name</b>	N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2 <i>RS</i> )-propyl]-( <i>R</i> )-cysteinyl-( <i>S</i> )-seryl-( <i>S</i> )-lysyl-( <i>S</i> )-lysyl-( <i>S</i> )-lysyl-( <i>S</i> )-lysine(5(6)-cyanine5) x 2 CF <sub>3</sub> COOH
<b>Synonyms</b>	P <sub>3</sub> C-SK <sub>4</sub> KKK(Cyanine5) x 2 TFA
<b>CAS</b>	Not available
<b>MW / Formula</b>	2011 • 228.1 / C <sub>113</sub> H <sub>193</sub> N <sub>12</sub> O <sub>14</sub> S

**Vial content** 100 µg

### Description



Pam<sub>3</sub>Cys-SK<sub>4</sub>KKK(Cy5) is a selectively labelled analogue of Pam<sub>3</sub>Cys-SK<sub>4</sub>KKK (product code L2000). It is labelled with cyanine5 carboxylic acid via the side chain of the C-terminal lysine. Cy5 has an excitation maximum of 646 nm and an emission maximum of 662 nm.

Lipopeptides are valuable tools for basic research in innate and acquired immunity. The synthetic lipopeptide Pam<sub>3</sub>Cys-SK<sub>4</sub>KKK is described to elicit cellular responses through TLR1/TLR2 heterodimers which involves downstream NF-κB activation and cytokine release. Pam<sub>3</sub>Cys-SK<sub>4</sub>KKK is based on the structure of the N-terminus of bacterial lipoproteins and is also well known as potent immune adjuvant. The crystal structure of the TLR1/TLR2 heterodimers with the synthetic ligand *R*-Pam<sub>3</sub>Cys-SK<sub>4</sub>KKK (*RR*-stereoisomer, product code L2048) has been elucidated.

### Packaging Reconstitution Storage

The fluorescently labelled lipopeptide is provided as a lyophilised, blue powder without any additives. It can be shipped at room temperature and should be stored at 4°C. Pam<sub>3</sub>Cys-SK<sub>4</sub>KKK(Cy5) can be reconstituted in endotoxin-free water (1 mg/ml stock solution). Through the use of either a homogeniser or sonicator, a homogenous solution or emulsion can be prepared. If you use an ultrasonic bath, take care of the vial labels. For further dilutions water, saline, buffer (pH ≤ 7.4) or media can be used. After reconstitution, the solution should be aliquoted and stored at or below -20°C. Repeated thawing and freezing should be avoided.

### Handling

Good laboratory technique should be employed in the safe handling of any lipopeptide product. If you are not fully trained or are unaware of the hazards involved, do not use this compound!  
Caution: Do not take internally! Avoid contact by all modes of exposure. Wear appropriate laboratory attire including a lab coat, gloves, mask and safety glasses. Do not mouth pipette, inhale, ingest or allow to come into contact with open wounds. Wash thoroughly any area of the body which comes into contact with the product. Avoid accidental autoinoculation by exercising extreme care when handling in conjunction with any injection device. This product is intended for research purposes by qualified personnel only. It is not intended for use in humans or as a diagnostic agent. EMC microcollections GmbH is not liable for any damages resulting from misuse or handling of this product.

# Product Information

## Pam<sub>3</sub>Cys-SK<sub>4</sub>KKK(Cy5)

For Research Purposes only. Not for use in Humans



### References

- K. Hantke, V. Braun (1973) Covalent binding of lipid to protein. Diglyceride and amide-linked fatty acid at the N-terminal end of the murein-lipoprotein of the *Escherichia coli* outer membrane. *Eur. J. Biochem.* 34, 284–296.
- K. Deres, H.-J. Schild, K.-H. Wiesmüller, G. Jung, H.-G. Rammensee (1989) In vivo Priming of Virus Specific Cytotoxic T Lymphocyte with Synthetic Lipopeptide Vaccine. *Nature* 342, 561-564.
- J. Metzger, K.-H. Wiesmüller, R. Schaudé, W. G. Bessler, G. Jung (1991) Synthesis of Novel Immunologically Active Tripalmitoyl-S-glycerylcysteinyl Lipopeptides as Useful Intermediates for Immunogen Preparations. *Int. J. Pept. Protein Res.* 37, 46-57.
- K.-H. Wiesmüller, W. G. Bessler, G. Jung (1992) Solid Phase Peptide Synthesis of Lipopeptide Vaccines Eliciting Epitope specific B-, T-Helper and T-Killer Cell Response. *Int. J. Pept. Protein Res.* 40, 255-260.
- A. O. Aliprantis, R. B. Yang, M. R. Mark, S. Suggett, B. Devaux, J. D. Radolf, G. P. Klimpel, P. Godowski, A. Zychlinsky (1999) Cell Activation and Apoptosis by Bacterial Lipoproteins Through Toll-like Receptor-2. *Science* 285, 736-739.
- S. Akira S. Mammalian (2003) Toll-like receptors. *Curr. Opin. Immunol.* 15, 5–11.
- M. S. Jin, S. E. Kim, J. Y. Heo, M. E. Lee, H. M. Kim, S.-G. Paik, H. Lee, J.-O. Lee (2007) Crystal Structure of the TLR1-TLR2 Heterodimer Induced by Binding of a Tri-Acylated Lipopeptide. *Cell* 130, 1071–1082.
- S. Voss, A. J. Ulmer, G. Jung, K.-H. Wiesmüller, R. Brock (2007) The activity of lipopeptide TLR2 agonists critically depends on the presence of solubilizers. *Eur. J. Immunol.* 37(12), 3489-3498.
- H. Kumar, T. Kawai, S. Akira (2009) Toll-like receptors and innate immunity. *Biochem. Biophys. Res. Comm.* 388, 621–625.
- D. T. Nguyen, L. de Witte, M. Ludlow, S. Yüksel, K.-H. Wiesmüller, T. B. Geijtenbeek, A. D. Osterhaus, R. L. de Swart (2010) The Synthetic Bacterial Lipopeptide Pam<sub>3</sub>CSK<sub>4</sub> Modulates Respiratory Syncytial Virus Infection Independent of TLR Activation. *PLoS Pathog.* 19, 6(8) pii:e1001049.
- A. Burger-Kentischer, I. S. Abele, D. Finkelmeier, K.-H. Wiesmüller, S. Rupp (2010) A new cell-based innate immune receptor assay for the examination of receptor activity, ligand specificity, signalling pathways and the detection of pyrogens. *J. Immunol. Methods* 30, 93-103.